Loading data for SCYX — first visit, this takes a few seconds.
SCYNEXIS Inc. (SCYX)
NasdaqCM: SCYX
· Real-Time Price · USD
5.67
+0.48 (9.25%)
At close: Aug 26, 2026, 8:00 PM
The price, the headline numbers and the latest news, in one place.
SCYNEXIS Inc. (SCYX) Stock Price, Analysis & Data
9.25% (1D)
No data available
| Bid | 4.14 |
| Market Cap | 56.41M |
| Revenue (ttm) | 19.22M |
| Net Income (ttm) | -10.23M |
| 1.10 | |
| -0.91 | |
| n/a | |
| -2.45 | |
| P/B (ttm) | 0.84 |
| P/S (ttm) | 2.94 |
| Earnings Date | Nov 4, 2026 |
| Ask | 6.92 |
| Volume | 220,377 |
| Avg. Volume (20D) | 137,957 |
| Open | 5.20 |
| Previous Close | 5.19 |
| Day's Range | 5.10 - 6.09 |
| 52-Week Range | 3.53 - 10.48 |
| Analyst | n/a |
| Price Target | n/a |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About SCYX
SCYNEXIS, Inc., a biotechnology company, engages in drug development for the treatment and prevention of difficult-to-treat and drug-resistant fungal infections in the United States. The company offers BREXAFEMME for the treatment of patients with vulvovaginal candidiasis and for the reduction in the incidence of recurrence. It also develops SCY-247, which is in Phase I clinical trial for the treatment of invasive fungal infections. The company w...
Sector Healthcare
IPO Date May 2, 2014
Employees 18
Stock Exchange NasdaqCM
Ticker Symbol SCYX
Website https://www.scynexis.com
Financial Performance
In 2025, SCYNEXIS's revenue was 20.6M, an increase of 449.95% compared to the previous year's 3.75M. Earnings were -8.61M, a decrease of -59.56%.
Financial StatementsEarnings Surprise
SCYNEXIS has released their quarterly earnings on Aug 10, 2026:
- Revenue of $0 misses estimates by $0, with -100.00% YoY decline.
- EPS of 0.63 exceeds estimates by 1.14, with 156.25% YoY growth.
SCYNEXIS Inc. is scheduled to release its earnings on Nov 4, 2026, during market hours.
Analysts project revenue of ... Upgrade
Analysts project revenue of ... Upgrade
Page 1 of 2